Replica Analytics, in collaboration with Health City, brings to you the 2021 Synthetic Data Summit. This focused event will present how synthetic data enables academia and the life sciences industry to responsibly use health data in research as well as product development and launch efforts.

Protecting privacy is a key requirement providing secondary access to help data. One of the primary benefits of synthetic data is that it is privacy protective – it is not considered to be personal information. We now have a powerful tool to democratize access to health information in a responsible way.

The Summit will explore current applications of synthetic data generation methods for data reuse and sharing, as well as looking ahead to what the future of synthetic data may look like with the rapid advancements in artificial intelligence (AI) and machine learning (ML). Three perspectives will be provided: academia, the life sciences industry, and funders.

Synthetic Data: The Future of Data Sharing

A brief introduction to the Summit and its objectives.

Presenters:

Khaled El Emam, Professor, School of Epidemiology and Public Health, University of Ottawa; Senior Scientist, CHEO Research Institute; and CEO, Replica Analytics

Time:

11am EDT – 11:05 am EDT

The Alberta Synthetic Data Project

We will kick off the Summit with a presentation of the Alberta Synthetic Data Project, to explore how synthetic data is currently being applied in the area of life sciences. Key questions this session will address include:

• What are some of the use cases for synthetic data in Alberta and why a focus on synthetic data for the region ?
• What is synthetic data ?
• How complex health system data was synthesized ?
• What are the privacy risks of synthetic data ?
• How good is the quality of synthetic data ?

Presenters:

Dean Eurich, Professor, School of Public Health, University of Alberta

Lucy Mosquera, Director of Data Science, Replica Analytics

Time:

11:05 am EDT – 11:30 am EDT (incl. Q&A)

Panel: Uses of Synthetic Data by the Life Sciences Industry

In this panel, we will hear from a number of life science companies (Merck, Novartis and Janssen) on how data synthesis is solving their companies’ data sharing and reuse problems.

Experiences with synthetic data at these three pharmaceutical companies will be discussed. Specific highlights:

• How can companies use synthetic data as a competitive advantage ?
• Why have the panelists pursued projects and/or investments in synthetic data ?
• Can the panelists describe their experiences with synthetic data ?
• How does synthetic data compare to alternative approaches to get access to different types of data ?
• Where do the panelists see synthetic data in the future / what is your prediction about where data synthesis is headed ?

Moderator:

Reg Joseph, CEO, Health City

Presenters:

Virginie Giroux, M.Sc., Director, Patient Access & HEOR, Merck

Stephen Bamford, Head of Clinical Data Standards & Transparency, The Janssen Pharmaceutical Companies of Johnson & Johnson

Janice Branson, Global Head of Advanced Methodology & Data Science, Novartis

Time:

11:30 am EDT – 12:30 pm EDT (incl. Q&A)

How Synthetic Data Will Transform Health Research and Innovation

Organizations that fund research have a strong interest in enabling data sharing. They fund many research projects in which data is collected and want to make that data useful and used as broadly as possible, while ensuring that the privacy of participants is protected. Synthetic data is one of technologies that some funding agencies are looking at to solve this problem. The purpose of this session is to understand the problem that funding agencies are trying to solve, how they see synthetic data solving that problem, and what their longer term vision is on the value of synthetic data and how will they make that vision a reality.

Presenters:

TBC

Time:

12:30 pm EDT – 1 pm EDT (incl. Q&A)

Register Here